FDA to Evaluate Idelalisib for Indolent Non-Hodgkin's Lymphoma Monthly Prescribing Reference The NDA submission was supported by a single arm Phase 2 study (Study 101-09) evaluating idelalisib in patients with iNHL that is refractory (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy. Idelalisib is an investigational ... FDA Approves Application Review For Refractory Indolent Non-Hodgkin's ... |
